Finally, including more diverse patient populations in future research ensures the generalizability of findings and identification of potential disparities in treatment responses. By addressing these future research directions, we can solidify the evidence base and optimize clinical decision-making for managing heart failure in T2DM patients using SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.